← Back to Screener
Lexaria Bioscience Corp. Common Stock (LEXX)
Price$0.64
Value ScoreD
Growth ScoreD
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-49.48%
Price vs S&P 500 (4W)4.47%
VGM Score32.85
Market Capitalization$15.79M
All Metrics
Book Value / Share (Quarterly)$0.27
P/TBV (Annual)6.42x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)39.51%
Cash Flow / Share (Quarterly)$-0.39
Price vs S&P 500 (YTD)-4.92%
Gross Margin (TTM)100.00%
Net Profit Margin (TTM)-2156.23%
EPS (TTM)$-0.48
10-Day Avg Trading Volume0.09M
EPS Excl Extra (TTM)$-0.48
Revenue Growth (5Y)17.89%
EPS (Annual)$-0.66
ROI (Annual)-398.09%
Gross Margin (Annual)99.61%
Net Profit Margin (5Y Avg)-1837.15%
Cash / Share (Quarterly)$0.21
Revenue Growth QoQ (YoY)-88.51%
ROA (Last FY)-285.07%
Revenue Growth TTM (YoY)-30.03%
EBITD / Share (TTM)$-0.45
ROE (5Y Avg)-162.22%
Operating Margin (TTM)-2157.06%
Cash Flow / Share (Annual)$-0.55
P/B Ratio2.39x
P/B Ratio (Quarterly)2.68x
Net Income / Employee (Annual)$-1,700,300
EV / Revenue (TTM)28.97x
ROA (TTM)-162.53%
EV / EBITDA (TTM)122.04x
EPS Incl Extra (Annual)$-0.66
Current Ratio (Annual)2.32x
Quick Ratio (Quarterly)24.74x
3-Month Avg Trading Volume0.17M
52-Week Price Return-35.66%
Revenue / Employee (TTM)$52,600
Tangible BV / Share (Quarterly)$0.25
P/S Ratio (Annual)22.37x
Asset Turnover (Annual)0.17x
52-Week High$1.55
Operating Margin (5Y Avg)-1896.92%
EPS Excl Extra (Annual)$-0.66
CapEx CAGR (5Y)51.95%
Tangible BV CAGR (5Y)3.67%
26-Week Price Return-41.56%
Quick Ratio (Annual)1.56x
13-Week Price Return-17.70%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)26.88x
Enterprise Value$10.66M
Revenue / Share Growth (5Y)-18.92%
Asset Turnover (TTM)0.06x
Book Value / Share Growth (5Y)-28.93%
Revenue / Employee (Annual)$100,800
Inventory Turnover (Annual)1.50x
Pretax Margin (Annual)-1687.36%
Cash / Share (Annual)$0.10
3-Month Return Std Dev92.89%
Gross Margin (5Y Avg)85.36%
Net Income / Employee (TTM)$-1,361,400
ROE (Last FY)-398.09%
EPS Basic Excl Extra (Annual)$-0.66
P/FCF (TTM)68.65x
Receivables Turnover (TTM)4.54x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.48
Receivables Turnover (Annual)4.54x
ROI (TTM)-190.06%
P/S Ratio (TTM)42.91x
Pretax Margin (5Y Avg)-1896.92%
Revenue / Share (Annual)$0.04
Tangible BV / Share (Annual)$0.14
Price vs S&P 500 (52W)-60.02%
Year-to-Date Return3.24%
5-Day Price Return3.36%
EPS Normalized (Annual)$-0.66
ROA (5Y Avg)-137.97%
Net Profit Margin (Annual)-1686.00%
Month-to-Date Return5.81%
Cash Flow / Share (TTM)$-1.13
EBITD / Share (Annual)$-0.66
Operating Margin (Annual)-1687.36%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-162.22%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.48
P/TBV (Quarterly)2.81x
P/B Ratio (Annual)5.76x
Inventory Turnover (TTM)1.50x
Pretax Margin (TTM)-2157.06%
Book Value / Share (Annual)$0.15
Price vs S&P 500 (13W)-25.95%
Beta0.34x
P/FCF (Annual)68.65x
Revenue / Share (TTM)$0.02
ROE (TTM)-190.06%
52-Week Low$0.46
vGradeD
gGradeD
mGradeC
vgmGradeD
Show chart for
Earnings Surprise History
Q2 26-0.06est. -0.10
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LEXXLexaria Bioscience Corp. Common Stock | D | D | C | $0.64 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Lexaria Bioscience is a biotechnology company that generates revenue by licensing its proprietary DehydraTECH drug delivery technology, which enhances the bioavailability and effectiveness of active pharmaceutical ingredients. The platform has broad applicability across therapeutics including GLP-1 drugs, pain medications, cannabinoids, and more, serving disease areas like diabetes, weight loss, and hypertension. DehydraTECH can be incorporated into multiple product formats—tablets, capsules, beverages, and foods—for use in pharmaceuticals, nutraceuticals, and consumer products.